Literature DB >> 11370937

Beryllium sensitization, chronic beryllium disease, and exposures at a beryllium mining and extraction facility.

D Deubner1, M Kelsh, M Shum, L Maier, M Kent, E Lau.   

Abstract

In this study, we examine beryllium sensitization, chronic beryllium disease (CBD), and workplace exposures at a beryllium mining (mine) and extraction facility (mill) in Delta, Utah. Historical airborne beryllium data collected between 1970-1999 included general area (GA), breathing zone (BZ), and personal lapel (LP) measurements and calculations of job-specific quarterly daily-weighted averages (DWVAs). We compared GA, BZ, and DWA data to airborne beryllium data from a mixed beryllium products facility and a beryllium ceramics facility located in Elmore, Ohio and Tucson, Arizona, respectively. At the Delta facility, jobs involving beryllium hydrolysis and wet-grinding activities had the highest air concentrations; annual median GA concentrations were less than 0.3 microg/m3 or both areas. Annual median GA sample concentrations ranged from 0.1-0.4 microg/m(-3) at Delta. These levels were generally lower than Elmore (0.1-1.0 microg/m3) and were comparable to the Tucson facility (0.1-0.4 microg/m3). Median BZ concentrations were higher, whereas DWAs were lower at the Delta facility than at the other two facilities. Among the 87 employees at the Delta facility, 75 participated in the medical survey; there were three persons sensitized, one with CBD. The individual with CBD previously worked at the Elmore facility for 10 years. Cumulative CBD incidence rates were significantly lower at the Delta facility: 0.3 percent compared to 2.0 percent for Elmore and 2.5 percent for the Tucson facility. Sensitization and CBD prevalence rates determined from cross-sectional surveys for the Delta facility were lower than but not significantly different from rates at the other two facilities. There was no sensitization or CBD among those who worked only at the mine where the only exposure to beryllium results from working with bertrandite ore. Although these results are derived from a small sample, this study suggests that the form of beryllium may affect the likelihood of developing CBD. Specifically, exposure to beryl and bertrandite ore dusts or to beryllium salts, in the absence of exposure to beryllium oxide particulates appears to pose a lower risk for developing CBD.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11370937     DOI: 10.1080/104732201750169697

Source DB:  PubMed          Journal:  Appl Occup Environ Hyg        ISSN: 1047-322X


  8 in total

1.  Beryllium's public relations problem: protecting workers when there is no safe exposure level.

Authors:  David Michaels; Celeste Monforton
Journal:  Public Health Rep       Date:  2008 Jan-Feb       Impact factor: 2.792

2.  The bioinorganic chemistry and associated immunology of chronic beryllium disease.

Authors:  Brian L Scott; T Mark McCleskey; Anu Chaudhary; Elizabeth Hong-Geller; S Gnanakaran
Journal:  Chem Commun (Camb)       Date:  2008-05-09       Impact factor: 6.222

3.  Efficacy of a program to prevent beryllium sensitization among new employees at a copper-beryllium alloy processing facility.

Authors:  Carrie A Thomas; Rachel L Bailey; Michael S Kent; David C Deubner; Kathleen Kreiss; Christine R Schuler
Journal:  Public Health Rep       Date:  2009 Jul-Aug       Impact factor: 2.792

4.  Release of beryllium from mineral ores in artificial lung and skin surface fluids.

Authors:  Matthew G Duling; Aleksandr B Stefaniak; Robert B Lawrence; Steve J Chipera; M Abbas Virji
Journal:  Environ Geochem Health       Date:  2011-08-25       Impact factor: 4.609

5.  The uses and adverse effects of beryllium on health.

Authors:  Ross G Cooper; Adrian P Harrison
Journal:  Indian J Occup Environ Med       Date:  2009-08

6.  Performance of the beryllium blood lymphocyte proliferation test based on a long-term occupational surveillance program.

Authors:  Ellen P Donovan; Marc E Kolanz; David A Galbraith; Pamela S Chapman; Dennis J Paustenbach
Journal:  Int Arch Occup Environ Health       Date:  2007-05-05       Impact factor: 3.015

Review 7.  Beryllium metal II. a review of the available toxicity data.

Authors:  Christian Strupp
Journal:  Ann Occup Hyg       Date:  2010-12-31

8.  Clinical tool for disease phenotyping in granulomatous lung disease.

Authors:  Lori J Silveira; Matthew Strand; Michael V Van Dyke; Margaret M Mroz; Anna V Faino; Dana M Dabelea; Lisa A Maier; Tasha E Fingerlin
Journal:  PLoS One       Date:  2017-11-16       Impact factor: 3.240

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.